Name PRICE MARKET CAPITALIZATION PRICE TO EARNINGS RATIO DIVIDEND YIELD SYMBOL EXCHANGE PRICE PERCENT DIFFERENCE YEAR TO DATE PRICE PERCENT DIFFERENCE 5 YEAR CHART 1 YEAR CHART

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.

https://www.allakos.com


ALLK $36.30 -1.72 (-4.52%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 1.64 Billion
EPS 0.14 P/E Ratio 0.00
Previous Earnings Thu, Nov 8, 2018
Latest Earnings Thu, Mar 14, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

36.30 1.64 0.00 0.00 ALLK NASDAQ -4.52 -30.18 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALLK&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALLK&exchange=NASDAQ&chart=1

Symbol Surfing has been referenced on Barrons, CNN & Investor Place.

About | Blog | Advertising | Terms | info@symbolsurfing.com

Investing Quotes #Legendary


Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.

Some links on this website are advertisements and/or affiliate links and Symbol Surfing receives compensation.

©2019 Symbol Surfing All Rights Reserved. Privacy Policy | ^Top